You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNadroparin
Accession NumberDB08813
TypeSmall Molecule
GroupsApproved
DescriptionNadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fraxiparinesolution9500 unitintravenous; subcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
Fraxiparinesolution9500 unitintravenous; subcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
Fraxiparinesolution9500 unitintravenous; subcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
Fraxiparinesolution9500 unitintravenous; subcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
Fraxiparinesolution9500 unitintravenous; subcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
Fraxiparine Fortesolution19000 unitintravenous; subcutaneousAspen Pharma Trading Limited1999-06-22Not applicableCanada
Fraxiparine Fortesolution19000 unitintravenous; subcutaneousAspen Pharma Trading Limited1999-06-22Not applicableCanada
Fraxiparine Fortesolution19000 unitintravenous; subcutaneousAspen Pharma Trading Limited1999-06-22Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nadroparin calcium
ThumbNot applicableDBSALT001135
Categories
UNIINot Available
CAS number9041-08-1
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationNadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction
PharmacodynamicsNadroparin is a low molecular weight heparin that is composed of a heterogeneous mixture of sulfated polysaccaride glycosaminoglycan chains. Th mean molecular weight is approximately 4300 daltons. The ratio of anti-Xa activity to anti-IIa is 3.5:1 whereas it is about 1:1 for heparin. Its use should be avoided in patients with a creatinine clearance less than 40mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.
Mechanism of actionThe mechanism of action for nadroparin is similar to all other LMWHs. Like all LMWHs, nadroparin has a pentasaccharide sequence which binds to ATIII, which potentiates the action of ATIII. This complex greatly accelerates the inactivation of factor Xa and factor IIa. As a result, the coagulation cascade is inhibited.
Related Articles
AbsorptionAbsorption is linear. The bioavailability of nadroparin after subcutaneous administration is about 89%.
Volume of distribution

3.59L

Protein bindingMuch lower compared to heparin, which has over 90% protein bound.
Metabolism

Nadroparin is metabolized in the liver.

Route of eliminationNadroparin is eliminated via the kidneys through non-saturable mechanisms.
Half lifeIn healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.
Clearance

The clearance of nadroparin is 21.4 +/- 7.0mL/min

ToxicityOsteopenia with extended use, skin necrosis, thrombocytosis, severe immunologically-mediated thrombocytopenia, eosinophilia (rare), calcinosis rarely occurs at the injection site, severe bleeding, transient elevation of liver transaminases.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Solutionintravenous; subcutaneous9500 unit
Solutionintravenous; subcutaneous19000 unit
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis ReferenceNot Available
General References
  1. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thebault JJ: Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995 Apr;73(4):630-40. [PubMed:7495071 ]
  2. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165 ]
  3. Lai KN, Wang AY, Ho K, Szeto CC, Li M, Wong LK, Yu AW: Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis. 1996 Nov;28(5):721-6. [PubMed:9158210 ]
  4. Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sie P: Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. Thromb Haemost. 1998 Feb;79(2):338-41. [PubMed:9493587 ]
  5. Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H: Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci. 1999 May;8(2):119-25. [PubMed:10210734 ]
  6. Ng HJ, Lee LH: Heparin-induced thrombocytopenia: acknowledging its presence in low-molecular weight heparin therapy. Int J Hematol. 2003 Feb;77(2):185-7. [PubMed:12627856 ]
  7. Breddin HK: Prophylaxis and treatment of deep-vein thrombosis. Semin Thromb Hemost. 2000;26 Suppl 1:47-52. [PubMed:11011806 ]
  8. Haas SK: Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost. 2002 Dec;28(6):577-84. [PubMed:12536351 ]
  9. Davis R, Faulds D: Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging. 1997 Apr;10(4):299-322. [PubMed:9108990 ]
  10. Iaremchuk AIa, Zotov AS, Cheshuk VE, Anikuc'ko NF, Zakhartseva LM, Diatel MV, Kravchenko AV, Lobanova OE, Sidorchuk OI: [Clinical effectiveness of nadroparin calcium in the surgical treatment of breast cancer]. Vopr Onkol. 2003;49(2):205-8. [PubMed:12785206 ]
  11. Vitale FV, Rotondo S, Sessa E, Antonelli G, Colina P, Parisi A, Giamo V, Ferrau F: Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases. J Oncol Pharm Pract. 2011 Jun;17(2):141-4. doi: 10.1177/1078155209353465. Epub 2009 Dec 16. [PubMed:20015933 ]
  12. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009 Oct;10(10):943-9. doi: 10.1016/S1470-2045(09)70232-3. Epub 2009 Aug 31. [PubMed:19726226 ]
External LinksNot Available
ATC CodesB01AB06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabAbciximab may increase the anticoagulant activities of Nadroparin.
AceclofenacAceclofenac may increase the anticoagulant activities of Nadroparin.
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Nadroparin.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Nadroparin.
AdapaleneAdapalene may increase the anticoagulant activities of Nadroparin.
AliskirenNadroparin may increase the hyperkalemic activities of Aliskiren.
AllylestrenolThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Allylestrenol.
AlprostadilAlprostadil may increase the anticoagulant activities of Nadroparin.
AlteplaseAlteplase may increase the anticoagulant activities of Nadroparin.
AltrenogestThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Altrenogest.
ALX-0081ALX-0081 may increase the anticoagulant activities of Nadroparin.
AmilorideNadroparin may increase the hyperkalemic activities of Amiloride.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Nadroparin.
AnagrelideAnagrelide may increase the anticoagulant activities of Nadroparin.
AncrodAncrod may increase the anticoagulant activities of Nadroparin.
AnistreplaseAnistreplase may increase the anticoagulant activities of Nadroparin.
AntipyrineAntipyrine may increase the anticoagulant activities of Nadroparin.
Antithrombin III humanNadroparin may increase the anticoagulant activities of Antithrombin III human.
ApixabanApixaban may increase the anticoagulant activities of Nadroparin.
ApremilastApremilast may increase the anticoagulant activities of Nadroparin.
AprotininThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Aprotinin.
ArdeparinArdeparin may increase the anticoagulant activities of Nadroparin.
ArgatrobanArgatroban may increase the anticoagulant activities of Nadroparin.
AstaxanthinAstaxanthin may increase the anticoagulant activities of Nadroparin.
AzapropazoneAzapropazone may increase the anticoagulant activities of Nadroparin.
AzelastineAzelastine may increase the anticoagulant activities of Nadroparin.
Azilsartan medoxomilNadroparin may increase the hyperkalemic activities of Azilsartan medoxomil.
BalsalazideBalsalazide may increase the anticoagulant activities of Nadroparin.
BatroxobinBatroxobin may increase the anticoagulant activities of Nadroparin.
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Nadroparin.
BecaplerminBecaplermin may increase the anticoagulant activities of Nadroparin.
BemiparinBemiparin may increase the anticoagulant activities of Nadroparin.
BenazeprilNadroparin may increase the hyperkalemic activities of Benazepril.
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Nadroparin.
BeraprostBeraprost may increase the anticoagulant activities of Nadroparin.
BivalirudinBivalirudin may increase the anticoagulant activities of Nadroparin.
BromfenacBromfenac may increase the anticoagulant activities of Nadroparin.
CanagliflozinNadroparin may increase the hyperkalemic activities of Canagliflozin.
CandesartanNadroparin may increase the hyperkalemic activities of Candesartan.
CandoxatrilNadroparin may increase the hyperkalemic activities of Candoxatril.
CangrelorCangrelor may increase the anticoagulant activities of Nadroparin.
CaptoprilNadroparin may increase the hyperkalemic activities of Captopril.
CarprofenCarprofen may increase the anticoagulant activities of Nadroparin.
CastanospermineCastanospermine may increase the anticoagulant activities of Nadroparin.
CelecoxibCelecoxib may increase the anticoagulant activities of Nadroparin.
CertoparinNadroparin may increase the anticoagulant activities of Certoparin.
ChloroquineChloroquine may increase the anticoagulant activities of Nadroparin.
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Nadroparin.
CilazaprilNadroparin may increase the hyperkalemic activities of Cilazapril.
CilostazolCilostazol may increase the anticoagulant activities of Nadroparin.
Citric AcidCitric Acid may increase the anticoagulant activities of Nadroparin.
ClonixinClonixin may increase the anticoagulant activities of Nadroparin.
ClopidogrelClopidogrel may increase the anticoagulant activities of Nadroparin.
CollagenaseThe risk or severity of adverse effects can be increased when Nadroparin is combined with Collagenase.
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Nadroparin.
D-LimoneneD-Limonene may increase the anticoagulant activities of Nadroparin.
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Nadroparin.
DalteparinDalteparin may increase the anticoagulant activities of Nadroparin.
DanaparoidDanaparoid may increase the anticoagulant activities of Nadroparin.
DasatinibDasatinib may increase the anticoagulant activities of Nadroparin.
DeferasiroxThe risk or severity of adverse effects can be increased when Nadroparin is combined with Deferasirox.
DefibrotideDefibrotide may increase the anticoagulant activities of Nadroparin.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nadroparin is combined with Deoxycholic Acid.
DesirudinNadroparin may increase the anticoagulant activities of Desirudin.
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Nadroparin.
DesogestrelThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Desogestrel.
DextranNadroparin may increase the anticoagulant activities of Dextran.
Dextran 40Nadroparin may increase the anticoagulant activities of Dextran 40.
Dextran 70Nadroparin may increase the anticoagulant activities of Dextran 70.
Dextran 75Nadroparin may increase the anticoagulant activities of Dextran 75.
DiclofenacDiclofenac may increase the anticoagulant activities of Nadroparin.
DicoumarolDicoumarol may increase the anticoagulant activities of Nadroparin.
DienestrolDienestrol may decrease the anticoagulant activities of Nadroparin.
DienogestThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Dienogest.
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Nadroparin.
DiflunisalDiflunisal may increase the anticoagulant activities of Nadroparin.
DipyridamoleDipyridamole may increase the anticoagulant activities of Nadroparin.
DitazoleDitazole may increase the anticoagulant activities of Nadroparin.
DrospirenoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Drospirenone.
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Nadroparin.
DroxicamDroxicam may increase the anticoagulant activities of Nadroparin.
DydrogesteroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Dydrogesterone.
Edetic AcidEdetic Acid may increase the anticoagulant activities of Nadroparin.
EdoxabanEdoxaban may increase the anticoagulant activities of Nadroparin.
EnalaprilNadroparin may increase the hyperkalemic activities of Enalapril.
EnalaprilatNadroparin may increase the hyperkalemic activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the anticoagulant activities of Nadroparin.
EpinastineEpinastine may increase the anticoagulant activities of Nadroparin.
EpirizoleEpirizole may increase the anticoagulant activities of Nadroparin.
EplerenoneNadroparin may increase the hyperkalemic activities of Eplerenone.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Nadroparin.
EpoprostenolThe risk or severity of adverse effects can be increased when Nadroparin is combined with Epoprostenol.
EprosartanNadroparin may increase the hyperkalemic activities of Eprosartan.
EptifibatideEptifibatide may increase the anticoagulant activities of Nadroparin.
EstradiolEstradiol may decrease the anticoagulant activities of Nadroparin.
EstriolEstriol may decrease the anticoagulant activities of Nadroparin.
EstroneEstrone may decrease the anticoagulant activities of Nadroparin.
EtanerceptEtanercept may increase the anticoagulant activities of Nadroparin.
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Nadroparin.
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Nadroparin.
EtodolacEtodolac may increase the anticoagulant activities of Nadroparin.
EtofenamateEtofenamate may increase the anticoagulant activities of Nadroparin.
EtonogestrelThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Etonogestrel.
EtoricoxibEtoricoxib may increase the anticoagulant activities of Nadroparin.
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Nadroparin.
exisulindexisulind may increase the anticoagulant activities of Nadroparin.
FenbufenFenbufen may increase the anticoagulant activities of Nadroparin.
FenoprofenFenoprofen may increase the anticoagulant activities of Nadroparin.
FibrinolysinFibrinolysin may increase the anticoagulant activities of Nadroparin.
FloctafenineFloctafenine may increase the anticoagulant activities of Nadroparin.
FlunixinFlunixin may increase the anticoagulant activities of Nadroparin.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Nadroparin.
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Nadroparin.
ForasartanNadroparin may increase the hyperkalemic activities of Forasartan.
FosinoprilNadroparin may increase the hyperkalemic activities of Fosinopril.
GenisteinGenistein may decrease the anticoagulant activities of Nadroparin.
GestodeneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Gestodene.
HeminHemin may increase the anticoagulant activities of Nadroparin.
HeparinHeparin may increase the anticoagulant activities of Nadroparin.
HexestrolHexestrol may decrease the anticoagulant activities of Nadroparin.
HirulogHirulog may increase the anticoagulant activities of Nadroparin.
HMPL-004HMPL-004 may increase the anticoagulant activities of Nadroparin.
Hydroxyprogesterone caproateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Hydroxyprogesterone caproate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nadroparin is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nadroparin.
IbudilastIbudilast may increase the anticoagulant activities of Nadroparin.
IbuprofenIbuprofen may increase the anticoagulant activities of Nadroparin.
IbuproxamIbuproxam may increase the anticoagulant activities of Nadroparin.
IcatibantIcatibant may increase the anticoagulant activities of Nadroparin.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Nadroparin.
IfenprodilIfenprodil may increase the anticoagulant activities of Nadroparin.
IloprostIloprost may increase the anticoagulant activities of Nadroparin.
IloprostThe risk or severity of adverse effects can be increased when Nadroparin is combined with Iloprost.
IndomethacinIndomethacin may increase the anticoagulant activities of Nadroparin.
IndoprofenIndoprofen may increase the anticoagulant activities of Nadroparin.
IrbesartanNadroparin may increase the hyperkalemic activities of Irbesartan.
IsoxicamIsoxicam may increase the anticoagulant activities of Nadroparin.
KebuzoneKebuzone may increase the anticoagulant activities of Nadroparin.
KetoprofenKetoprofen may increase the anticoagulant activities of Nadroparin.
KetorolacKetorolac may increase the anticoagulant activities of Nadroparin.
LeflunomideLeflunomide may increase the anticoagulant activities of Nadroparin.
LepirudinLepirudin may increase the anticoagulant activities of Nadroparin.
LevonorgestrelThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Levonorgestrel.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Nadroparin.
LisinoprilNadroparin may increase the hyperkalemic activities of Lisinopril.
LornoxicamLornoxicam may increase the anticoagulant activities of Nadroparin.
LosartanNadroparin may increase the hyperkalemic activities of Losartan.
LoxoprofenLoxoprofen may increase the anticoagulant activities of Nadroparin.
LumiracoxibLumiracoxib may increase the anticoagulant activities of Nadroparin.
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Nadroparin.
MasoprocolMasoprocol may increase the anticoagulant activities of Nadroparin.
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Nadroparin.
MedrogestoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medrogestone.
Medroxyprogesterone acetateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Nadroparin.
Megestrol acetateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Megestrol acetate.
MeloxicamMeloxicam may increase the anticoagulant activities of Nadroparin.
MesalazineMesalazine may increase the anticoagulant activities of Nadroparin.
MestranolMestranol may decrease the anticoagulant activities of Nadroparin.
MetamizoleMetamizole may increase the anticoagulant activities of Nadroparin.
MilrinoneMilrinone may increase the anticoagulant activities of Nadroparin.
MoexiprilNadroparin may increase the hyperkalemic activities of Moexipril.
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Nadroparin.
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Nadroparin.
NabumetoneNabumetone may increase the anticoagulant activities of Nadroparin.
NaftifineNaftifine may increase the anticoagulant activities of Nadroparin.
NaproxenNaproxen may increase the anticoagulant activities of Nadroparin.
NCX 4016NCX 4016 may increase the anticoagulant activities of Nadroparin.
NepafenacNepafenac may increase the anticoagulant activities of Nadroparin.
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Nadroparin.
NimesulideNimesulide may increase the anticoagulant activities of Nadroparin.
NintedanibThe risk or severity of adverse effects can be increased when Nadroparin is combined with Nintedanib.
NorethisteroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Norethisterone.
ObinutuzumabThe risk or severity of adverse effects can be increased when Nadroparin is combined with Obinutuzumab.
OlmesartanNadroparin may increase the hyperkalemic activities of Olmesartan.
OlopatadineOlopatadine may increase the anticoagulant activities of Nadroparin.
OlsalazineOlsalazine may increase the anticoagulant activities of Nadroparin.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Nadroparin is combined with Omacetaxine mepesuccinate.
OmapatrilatNadroparin may increase the hyperkalemic activities of Omapatrilat.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Nadroparin.
OrgoteinOrgotein may increase the anticoagulant activities of Nadroparin.
OtamixabanOtamixaban may increase the anticoagulant activities of Nadroparin.
OxaprozinOxaprozin may increase the anticoagulant activities of Nadroparin.
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Nadroparin.
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Nadroparin.
ParecoxibParecoxib may increase the anticoagulant activities of Nadroparin.
ParnaparinParnaparin may increase the anticoagulant activities of Nadroparin.
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Nadroparin.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Nadroparin.
PerindoprilNadroparin may increase the hyperkalemic activities of Perindopril.
PhenindionePhenindione may increase the anticoagulant activities of Nadroparin.
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Nadroparin.
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Nadroparin.
PimecrolimusPimecrolimus may increase the anticoagulant activities of Nadroparin.
PirfenidonePirfenidone may increase the anticoagulant activities of Nadroparin.
PiroxicamPiroxicam may increase the anticoagulant activities of Nadroparin.
PlasminPlasmin may increase the anticoagulant activities of Nadroparin.
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Nadroparin.
PrasugrelPrasugrel may increase the anticoagulant activities of Nadroparin.
ProgesteroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Progesterone.
PropacetamolPropacetamol may increase the anticoagulant activities of Nadroparin.
Protein CNadroparin may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeNadroparin may increase the anticoagulant activities of Protocatechualdehyde.
PTC299PTC299 may increase the anticoagulant activities of Nadroparin.
QuinaprilNadroparin may increase the hyperkalemic activities of Quinapril.
QuinestrolQuinestrol may decrease the anticoagulant activities of Nadroparin.
RamiprilNadroparin may increase the hyperkalemic activities of Ramipril.
RescinnamineNadroparin may increase the hyperkalemic activities of Rescinnamine.
ResveratrolResveratrol may increase the anticoagulant activities of Nadroparin.
ReteplaseReteplase may increase the anticoagulant activities of Nadroparin.
ReviparinNadroparin may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Nadroparin.
RivaroxabanNadroparin may increase the anticoagulant activities of Rivaroxaban.
RofecoxibRofecoxib may increase the anticoagulant activities of Nadroparin.
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Nadroparin.
SalicylamideSalicylamide may increase the anticoagulant activities of Nadroparin.
Salicylic acidSalicylic acid may increase the anticoagulant activities of Nadroparin.
SalsalateSalsalate may increase the anticoagulant activities of Nadroparin.
SaprisartanNadroparin may increase the hyperkalemic activities of Saprisartan.
SaralasinNadroparin may increase the hyperkalemic activities of Saralasin.
SCH-530348SCH-530348 may increase the anticoagulant activities of Nadroparin.
SelexipagSelexipag may increase the anticoagulant activities of Nadroparin.
SeratrodastSeratrodast may increase the anticoagulant activities of Nadroparin.
SevofluraneSevoflurane may increase the anticoagulant activities of Nadroparin.
SpiraprilNadroparin may increase the hyperkalemic activities of Spirapril.
SpironolactoneNadroparin may increase the hyperkalemic activities of Spironolactone.
SRT501SRT501 may increase the anticoagulant activities of Nadroparin.
StreptokinaseStreptokinase may increase the anticoagulant activities of Nadroparin.
SugammadexSugammadex may increase the anticoagulant activities of Nadroparin.
SulfasalazineSulfasalazine may increase the anticoagulant activities of Nadroparin.
SulindacSulindac may increase the anticoagulant activities of Nadroparin.
SulodexideSulodexide may increase the anticoagulant activities of Nadroparin.
SuprofenSuprofen may increase the anticoagulant activities of Nadroparin.
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Nadroparin.
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nadroparin.
TasosartanNadroparin may increase the hyperkalemic activities of Tasosartan.
TelmisartanNadroparin may increase the hyperkalemic activities of Telmisartan.
TemocaprilNadroparin may increase the hyperkalemic activities of Temocapril.
TenecteplaseTenecteplase may increase the anticoagulant activities of Nadroparin.
TenoxicamTenoxicam may increase the anticoagulant activities of Nadroparin.
TepoxalinTepoxalin may increase the anticoagulant activities of Nadroparin.
TeriflunomideTeriflunomide may increase the anticoagulant activities of Nadroparin.
TesmilifeneTesmilifene may increase the anticoagulant activities of Nadroparin.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Nadroparin.
TiboloneTibolone may increase the anticoagulant activities of Nadroparin.
TicagrelorTicagrelor may increase the anticoagulant activities of Nadroparin.
TiclopidineTiclopidine may increase the anticoagulant activities of Nadroparin.
TinzaparinTinzaparin may increase the anticoagulant activities of Nadroparin.
TipranavirTipranavir may increase the anticoagulant activities of Nadroparin.
TirofibanTirofiban may increase the anticoagulant activities of Nadroparin.
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Nadroparin.
TolmetinTolmetin may increase the anticoagulant activities of Nadroparin.
TositumomabThe risk or severity of adverse effects can be increased when Nadroparin is combined with Tositumomab.
TrandolaprilNadroparin may increase the hyperkalemic activities of Trandolapril.
TranilastTranilast may increase the anticoagulant activities of Nadroparin.
TrapidilTrapidil may increase the anticoagulant activities of Nadroparin.
TreprostinilTreprostinil may increase the anticoagulant activities of Nadroparin.
TreprostinilThe risk or severity of adverse effects can be increased when Nadroparin is combined with Treprostinil.
TriamtereneNadroparin may increase the hyperkalemic activities of Triamterene.
TriflusalTriflusal may increase the anticoagulant activities of Nadroparin.
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Nadroparin.
UrokinaseUrokinase may increase the anticoagulant activities of Nadroparin.
ValdecoxibValdecoxib may increase the anticoagulant activities of Nadroparin.
ValsartanNadroparin may increase the hyperkalemic activities of Valsartan.
Vitamin EVitamin E may increase the anticoagulant activities of Nadroparin.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Nadroparin.
WarfarinWarfarin may increase the anticoagulant activities of Nadroparin.
XimelagatranXimelagatran may increase the anticoagulant activities of Nadroparin.
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Nadroparin.
ZeranolZeranol may decrease the anticoagulant activities of Nadroparin.
ZileutonZileuton may increase the anticoagulant activities of Nadroparin.
ZomepiracZomepirac may increase the anticoagulant activities of Nadroparin.
Food Interactions
  • Danshen, dong quai, evening primrose oil, gingko, policosanol, willowbark

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
Gene Name:
SERPINC1
Uniprot ID:
P01008
Molecular Weight:
52601.935 Da
References
  1. Davis R, Faulds D: Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging. 1997 Apr;10(4):299-322. [PubMed:9108990 ]
  2. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sialic acid binding
Specific Function:
Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with PSGL1.
Gene Name:
SELP
Uniprot ID:
P16109
Molecular Weight:
90833.105 Da
References
  1. Simonis D, Christ K, Alban S, Bendas G: Affinity and kinetics of different heparins binding to P- and L-selectin. Semin Thromb Hemost. 2007 Jul;33(5):534-9. [PubMed:17629851 ]
  2. Ludwig RJ, Alban S, Bistrian R, Boehncke WH, Kaufmann R, Henschler R, Gille J: The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost. 2006 Mar;95(3):535-40. [PubMed:16525583 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function:
Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor. In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regul...
Gene Name:
FOS
Uniprot ID:
P01100
Molecular Weight:
40694.855 Da
References
  1. Nagy Z, Turcsik V, Blasko G: The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 2009 Dec;15(4):689-92. doi: 10.1007/s12253-009-9204-7. [PubMed:19757196 ]
  2. Sustar V, Jansa R, Frank M, Hagerstrand H, Krzan M, Iglic A, Kralj-Iglic V: Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin. Blood Cells Mol Dis. 2009 May-Jun;42(3):223-7. doi: 10.1016/j.bcmd.2009.01.012. Epub 2009 Mar 3. [PubMed:19261492 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function:
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.
Gene Name:
MYC
Uniprot ID:
P01106
Molecular Weight:
48803.55 Da
References
  1. Nagy Z, Turcsik V, Blasko G: The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 2009 Dec;15(4):689-92. doi: 10.1007/s12253-009-9204-7. [PubMed:19757196 ]
  2. Sustar V, Jansa R, Frank M, Hagerstrand H, Krzan M, Iglic A, Kralj-Iglic V: Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin. Blood Cells Mol Dis. 2009 May-Jun;42(3):223-7. doi: 10.1016/j.bcmd.2009.01.012. Epub 2009 Mar 3. [PubMed:19261492 ]
Comments
comments powered by Disqus
Drug created on June 14, 2011 23:17 / Updated on August 17, 2016 12:24